Medifast (NYSE:MED – Free Report) had its price target reduced by DA Davidson from $17.00 to $16.50 in a research report report published on Wednesday,Benzinga reports. They currently have a neutral rating on the specialty retailer’s stock.
Medifast Price Performance
MED opened at $14.71 on Wednesday. The business’s 50-day moving average is $16.25 and its two-hundred day moving average is $17.97. Medifast has a 1 year low of $13.57 and a 1 year high of $42.68. The firm has a market capitalization of $160.96 million, a PE ratio of 81.74 and a beta of 1.14.
Medifast (NYSE:MED – Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.26. Medifast had a net margin of 0.35% and a return on equity of 10.64%. The firm had revenue of $119.00 million for the quarter, compared to the consensus estimate of $114.25 million. As a group, sell-side analysts expect that Medifast will post 0.51 EPS for the current year.
Institutional Inflows and Outflows
Medifast Company Profile
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Stories
- Five stocks we like better than Medifast
- How to Invest in Small Cap Stocks
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- How to Plot Fibonacci Price Inflection Levels
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.